Risk of Retinopathy in Diabetic Patients Taking Semaglutide

The chapter explores the connection between diabetes medications, specifically semaglutide, and the potential risk of retinopathy in patients. It discusses clinical trial insights from Sustain, Rubelsis, and Flow, highlighting the impact of improved glycemic control on retinopathy complications. The speakers stress the importance of monitoring eye health and coordinating medication between specialists to mitigate risks.